Biosynex Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Larry Abensur

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	9.3yrs
Participación del CEO	6.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	9.3yrs

Actualizaciones recientes de la dirección

Recent updates

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Aug 16

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

Jun 29

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Mar 12

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

Jan 20

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

May 05

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Dec 01

CEO

Larry Abensur

9.3yrs

Permanencia

Mr. Larry Abensur has served as a Director at Biosynex S.A. since June 24, 2015 and serves as the Chief Executive Officer at Biosynex SA. He serves as the Chairman of Biosynex S.A. Mr. Abensur serves as th...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Larry Abensur	Chairman & CEO	9.3yrs	sin datos	6.2% € 2.8m
Thierry Paper	Deputy CEO & Director	9.3yrs	€96.00k	0.99% € 444.7k
Thomas Lamy	Deputy CEO & Director	9.3yrs	sin datos	1.56% € 698.8k
Felix Agbalika	Member of Scientific Advisory Board	no data	sin datos	sin datos
Emmanuel Drouet	Member of Scientific Advisory Board	no data	sin datos	sin datos
Denis Gallot	Member of Scientific Advisory Board	no data	sin datos	sin datos
Vincent Sapin	Member of Scientific Advisory Board	no data	sin datos	sin datos
Marc Noizet	Member of Scientific Advisory Board	no data	sin datos	sin datos
Elie Fraenckel	Director	no data	sin datos	sin datos

9.3yrs

Permanencia media

Junta con experiencia: La junta directiva de ALBIO se considera experimentada (9 años de antigüedad promedio).

Biosynex Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Biosynex SA, Annual General Meeting, Jun 07, 2024

No independent directors

No independent directors

Recent updates

Biosynex SA's (EPA:ALBIO) Shares Bounce 28% But Its Business Still Trails The Industry

Biosynex SA (EPA:ALBIO) Not Doing Enough For Some Investors As Its Shares Slump 30%

New major risk - Share price stability

Biosynex SA, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: €3.45 loss per share (vs €1.53 profit in FY 2022)

Biosynex SA (EPA:ALBIO) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

New minor risk - Shareholder dilution

Biosynex SA's (EPA:ALBIO) Shares Not Telling The Full Story

First half 2023 earnings released: €1.94 loss per share (vs €2.99 profit in 1H 2022)

New minor risk - Market cap size

New major risk - Earnings quality

Biosynex SA (ENXTPA:ALBIO) acquired 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) signed an agreement to acquire 57.33% interest in ProciseDx Inc. from Nestlé HealthCare Nutrition, Inc., other shareholders, employees, former employees and investors.

Biosynex SA (ENXTPA:ALBIO) acquired Eye Care activity from LABORATOIRES INNOXA.

Investor sentiment improves as stock rises 16%

Returns On Capital Are Showing Encouraging Signs At Biosynex (EPA:ALBIO)

Investor sentiment deteriorates as stock falls 22%

Full year 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) entered into a definitive merger agreement to acquire Chembio Diagnostics, Inc. (NasdaqCM:CEMI) for $17.2 million.

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) acquired 75% stake in Medkoncept A/S.

Investors Shouldn't Overlook Biosynex's (EPA:ALBIO) Impressive Returns On Capital

Investor sentiment improved over the past week

No independent directors

First half 2022 earnings released

Biosynex SA (ENXTPA:ALBIO) acquired Doc2u SAS on October 12, 2022.

Biosynex (EPA:ALBIO) Could Easily Take On More Debt

Biosynex SA (ENXTPA:ALBIO) alongside the two founders acquired Bhr Pharmaceuticals Limited.

Upcoming dividend of €2.00 per share

Full year 2021 earnings released: EPS: €10.08 (vs €3.52 in FY 2020)

No independent directors

Biosynex SA (ENXTPA:ALBIO) acquired PrimaDiag SAS.

Biosynex SA (ENXTPA:ALBIO) acquired Para'kito.

Full year 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Biosynex SA (ENXTPA:ALBIO) signed a binding letter of offer to acquire Human Health Business of Enalees.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

If You Like EPS Growth Then Check Out Biosynex (EPA:ALBIO) Before It's Too Late

Biosynex SA (ENXTPA:ALBIO) commences an Equity Buyback Plan for 10% of its issued share capital, for €4.5 million, under the authorization approved on June 8, 2020.

Here's Why I Think Biosynex (EPA:ALBIO) Is An Interesting Stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biosynex SA has completed a Follow-on Equity Offering in the amount of €15 million.

Investor sentiment deteriorated over the past week

New 90-day high: €20.60

Investor sentiment improved over the past week

We Think Biosynex (EPA:ALBIO) Can Stay On Top Of Its Debt

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: €19.90

First half earnings released

New 90-day high: €13.50

New 90-day high: €12.50

CEO

Permanencia

Miembros de la Junta

Permanencia media